Lupin on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America.
The company in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, it said in a statement.
The Mumbai-based drug maker's product is a generic version of Bristol-Myers Squibb Company's Sprycel tablets.
As per IQVIA MAT data, Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Are Synthetic Food Dyes Harmful to Children? Here’s What the Science Says Elon Musk's Neuralink Gets FDA's 'Breakthrough Device' Tag for Implant Aimed at Restoring Vision Elon Musk's Neuralink Gets Go Ahead For Brain Chip Implant In 2nd Patient: Report "Thousand Times Better...": Delhi Lt Governor's Surprise For AAP's Atishi "Violation Of Sovereignty, Abuse Of Power": Kanwal Sibal On US Report On Adani Group "World War 3 Has Begun": Ukraine Ex-Military Commander Amid Russia Conflict Bastar Will Be Maoist-Free Very Soon, Says Chhattisgarh Minister Arun Sao Petrol Pump Owner, Son Shot At Over Bill In UP's Kaushambi: Police Indian Researchers Find Method To Decode Monkeypox Virus, Aid Diagnostics Track Latest News Live on NDTV.com and get news updates from India and around the world.